RVTYHealthcare · Diagnostics & ResearchThe 17 Wall Street analysts covering Revvity, Inc. hold a median 12-month price target of $122 — -0.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 22 Aug 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Revvity, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (92): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Growth (55): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (13): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on RVTY, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −0.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Aug 2026 | Evercore ISI Group | Maintains | Outperform | $125 → $126 |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | $110 → $125 |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 26 June 2026 | Bernstein | Reinstates | Market Perform | $115 |
| 2 June 2026 | Wolfe Research | Assumes | Peer Perform | — |
| 7 May 2026 | Barclays | Maintains | Equal-Weight | — |
| 6 May 2026 | JP Morgan | Maintains | Neutral | — |
| 6 May 2026 | Stifel | Maintains | Hold | — |
| 6 May 2026 | TD Cowen | Maintains | Buy | — |
| 4 May 2026 | Baird | Maintains | Outperform | — |
| 14 Apr 2026 | Barclays | Downgrade | Equal-Weight | — |
| 14 Apr 2026 | Goldman Sachs | Maintains | Neutral | — |
| 31 Mar 2026 | JP Morgan | Maintains | Neutral | — |
| 3 Feb 2026 | Barclays | Maintains | Overweight | — |
| 3 Feb 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 3 Feb 2026 | Jefferies | Maintains | Hold | — |
| 3 Feb 2026 | JP Morgan | Maintains | Neutral | — |
| 3 Feb 2026 | TD Cowen | Maintains | Buy | — |
| 3 Feb 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 15 Dec 2025 | Barclays | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RVTY appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Aug 2026, Revvity, Inc. returned +31.0% against +19.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 13% of US stocks
Cheaper than 26% of US stocks
Cheaper than 48% of US stocks
Cheaper than 18% of US stocks
Higher than 30% of US stocks
Higher than 31% of US stocks
Higher than 68% of US stocks
Higher than 75% of US stocks
Higher than 66% of US stocks
Higher than 50% of US stocks
Higher than 61% of US stocks
Higher than 4% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Revvity, Inc. has a market value of $13.9B and an enterprise value of $16.2B.
Revenue in the twelve months to 31 Mar 2026: $2.9B. The latest quarter grew 1.3% year on year.
Net income over the same four quarters: $239.7M, a 8.3% net margin.
Diluted earnings per share, trailing twelve months: $2.09.
Free cash flow in the twelve months to 31 Mar 2026: $492.7M, after $77.3M of capital spending.
Revvity, Inc. spent $753.7M on share buybacks and $32.2M on dividends in the twelve months to 31 Mar 2026.
Trailing P/E: 59.4×; forward P/E: 21.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.23%, paying out 13% of earnings.
Revvity, Inc. employs 11,000 people — $264K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Revvity, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research reports that recent movements in the options market warrant close attention to Revvity (RVTY) stock. The article highlights the activity in RVTY options as a point of interest for investors.
Why it matters — Revvity watchers would care because unusual options activity can signal how investors are positioning around the stock.
Revvity launched SuperFlex, a compact automated prenatal screening system aimed at enabling rapid in-house testing for smaller labs and clinics. The system is designed to expand access to in-house prenatal screening in these settings.
Why it matters — RVTY watchers would care because the new product extends Revvity's prenatal screening offering to smaller labs and clinics, potentially broadening its customer base in that segment.
Revvity, Inc. announced it will present at three upcoming investor conferences: the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026, featuring CEO Prahlad Singh; the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026, featuring CFO Max Krakowiak; and Baird's 2026 Global Healthcare Conference.
Why it matters — Revvity watchers may be interested as the company's CEO and CFO will provide updates and interact with investors at these major healthcare industry conferences.
Revvity announced the launch of its SuperFlex prenatal screening system, a compact, CE-IVDR certified immunoassay instrument designed for laboratories and clinics with lower-volume workflows. The system supports testing for preeclampsia, a condition affecting 2–8% of pregnancies.
Why it matters — The launch broadens Revvity's prenatal screening product line and expands its offering into preeclampsia testing, a growing area of maternal-health screening.
Revvity reported second-quarter results above expectations and raised its full-year outlook, driven by strength in diagnostics, improving pharma and biotech demand, and growing orders for AI-enabled drug discovery workflows.
Why it matters — The upgraded guidance and demand signals across diagnostics, pharma, and AI-driven drug discovery suggest improving business momentum for Revvity.
The 17 Wall Street analysts covering Revvity, Inc. have a median 12-month price target of $122, with estimates ranging from $100 to $145. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 17 analysts covering Revvity, Inc., 6 rate it a Buy, 11 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Revvity, Inc. 94 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Revvity, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (92 of 100).
No one can know that. What the data says: the median 12-month target from 17 analysts implies -0.8% from the last close, and Ticker Nerd's factor model ranks Revvity, Inc. 94 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Revvity, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RVTY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $100 to $145 over the next 12 months.
Revvity, Inc. returned +31.0% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Revvity Inc. is a health science tools and diagnostics company that provides end-to-end solutions for research, development, testing, and clinical use.
The most recent item we track (Zacks Investment Research, 24 Aug 2026): "Is the Options Market Predicting a Spike in Revvity Stock?". Zacks Investment Research reports that recent movements in the options market warrant close attention to Revvity (RVTY) stock. The article highlights the activity in RVTY options as a point of interest for investors.
Revvity Inc. is a health science tools and diagnostics company that provides end-to-end solutions for research, development, testing, and clinical use. The company operates through two main segments: Life Sciences and Diagnostics, serving customers across pharmaceutical and biotechnology companies, diagnostic laboratories, academic institutions, and government organizations. Its portfolio includes reagents, consumables, assays, instruments, software, and specialized services that support workflows from discovery through diagnosis. Revvity focuses on areas such as translational multi-omics, biomarker identification, imaging, screening, detection, informatics, reproductive health, immunodiagnostics, and genomic testing. It also supports applications in rare disease testing, newborn screening, hereditary cancer, and broader clinical laboratory services. Based in Waltham, Massachusetts, Revvity plays an important role in the healthcare and life sciences ecosystem by helping researchers, clinicians, and laboratories generate and analyze data across a wide range of scientific and diagnostic applications.
CEO Dr. Prahlad R. Singh Ph.D. · 11,000 employees · United States · https://www.revvity.com
